Closed-Loop Artificial Pancreas PancreaBot Receives FDA Approval: Diabetes Management Enters Full Automation Era

Closed-Loop Artificial Pancreas PancreaBot Receives FDA Approval

On June 4, 2028, US company BetaBionics announced that its fully closed-loop artificial pancreas system PancreaBot received FDA approval. This is the first diabetes management system to achieve "full closed-loop" control — once worn, patients need not measure blood glucose, calculate insulin doses, or perform manual injections.

From Hybrid to Full Closed-Loop

Previous artificial pancreas systems were all "hybrid closed-loop" — they could automatically adjust basal insulin delivery but still required manual carbohydrate entry and dose confirmation at mealtimes. PancreaBot achieves full closed-loop through two innovations.

First, multi-sensor fusion. PancreaBot simultaneously uses continuous glucose monitoring (CGM), accelerometers, and skin conductance sensors, with AI algorithms predicting glucose trends 60 minutes ahead. Second, a dual-hormone system that delivers both insulin to lower glucose and micro-doses of glucagon to prevent and correct hypoglycemia.

Clinical Trial Results

The pivotal trial enrolled 480 Type 1 diabetes patients over six months. Time-in-range (TIR) improved from 62% baseline to 89%. Severe hypoglycemia events decreased by 92%, and diabetic ketoacidosis episodes dropped by 85%.

Harvard Medical School professor David Nathan commented: "89% TIR approaches non-diabetic levels. PancreaBot may be the most important advance in Type 1 diabetes management in 30 years."

Market Impact

Global diabetes prevalence exceeds 500 million, with approximately 5-10% being Type 1. Even covering only Type 1 patients, PancreaBot's potential user base is 25-50 million people.